Frakes says the number of HPV-positive oropharyngeal cancer diagnoses year to year is growing, though the number of survivors is proportionate.
Jessica Frakes, MD, assistant professor of radiation oncology, Department of Radiation Oncology, Moffitt Cancer Center, discusses patients treated with definitive radiation therapy (RT) for HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) and the detection of recurrences. Frakes says the number of HPV-positive oropharyngeal cancer diagnoses year to year is growing, though the number of survivors is proportionate.
According to Frakes, most recurrences and toxicities were found by posttreatment imaging at 3 months and physical examinations during the 6 months after treatment. She said patients experienced a low rate of permanent toxicity. Previous retrospective and prospective studies have shown that while HPV-associated cases of OPSCC are increasing in frequency, treatments result in decreased toxicities and increased survival.
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL
November 20th 2023In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
Read More
Neoadjuvant Pembro Plus Chemo Shows EFS Benefit at 5-Years in TNBC
November 13th 2023In an interview with Targeted Oncology, Peter Schmid, FRCP, MD, PhD, discussed the implication of findings from the KEYNOTE-522 trial of the addition of pembrolizumab to neoadjuvant chemotherapy in patients with high-risk triple-negative breast cancer.
Read More